Immuneering Corp (IMRX) is a pre-revenue clinical-stage biopharmaceutical company with a balance sheet dominated by liquid financial assets following a large equity raise in late 2025. Under a liquidation lens as of December 31, 2025, the recovery posture is modestly positive at face — a meaningful change from the prior year — driven entirely by the September 2025 capital markets activity that injected approximately $210 million gross across three transactions (August 2025 private placement at $3.95/share yielding $23.4M net, September 2025 Aventis/Sanofi private placement at $9.23/share yielding $23.4M net, and a September 2025 underwritten offering at $9.23/share yielding $164.1M net). Total assets are $232.0M against total liabilities of $13.5M, producing stated book equity of $218.5M. Liquidation recovery to equity is supported by: cash and cash equivalents of $128.6M (100% recovery), current marketable securities of $44.2M and non-current marketable securities of $44.2M — both Level 1 and Level 2 investment-grade instruments with de minimis unrealized net gain ($77K net) — recoverable at near-par. The combined liquid asset pool (cash plus marketable securities) equals approximately $217M, against which total liabilities of only $13.5M present minimal drag. After deducting all liabilities at face value, estimated liquidation recovery to equity approximates $215-217M, with the primary haircut being the $0.9M PP&E net (computer, lab equipment, leasehold improvements — apply 50-60% haircut = ~$0.5M), $6.7M goodwill (0% recovery), $0.3M finite-lived intangibles (0% recovery), and $0.3M other non-current assets. The operating lease liability of $3.8M stays at face value on the liability side; the corresponding ROU asset of $3.3M is excluded from liquidation asset value. Accrued liabilities of $7.8M (up from $5.0M at December 31, 2024) and accounts payable of $1.5M are the dominant current liabilities. No debt obligations exist. The Company burned $56.0M in FY2025 (net loss) versus $61.0M in FY2024; cash used in operations was $45.3M. The valuation allowance on deferred tax assets increased by $14.4M to $73.4M, confirming no deferred tax asset has liquidation value. The Aventis/Sanofi strategic investment is notable for its standstill, lock-up, and strategic process notification provisions, but these have no direct balance-sheet liquidation impact. The prior filing was the 10-Q for the period ended September 30, 2025, which captured the equity issuances as subsequent events; the 10-K confirms full consolidation of those proceeds into the balance sheet. Filing discusses CRO/CMO contract termination rights (30-day notice) in MD&A but does not separately XBRL-tag the committed contract values outstanding.
▼ Community Notes